The Potential Role of Nonpharmacologic Electrophysiology-Based Interventions in Improving Outcomes in Patients Hospitalized for Heart Failure

Norman C. Wang; Jonathan P. Piccini; Gregg C. Fonarow; Bradley Paul Knight; Matthew E. Harinstein; Javed Butler; Marc K. Lahiri; Marco Metra; Muthiah Vaduganathan; Mihai Gheorghiade

doi:10.1016/j.hfc.2013.04.007

The Potential Role of Nonpharmacologic Electrophysiology-Based Interventions in Improving Outcomes in Patients Hospitalized for Heart Failure

Norman C. Wang, Jonathan P. Piccini, Gregg C. Fonarow, Bradley Paul Knight, Matthew E. Harinstein, Javed Butler, Marc K. Lahiri, Marco Metra, Muthiah Vaduganathan, Mihai Gheorghiade^*

^*Corresponding author for this work

Medicine, Cardiology Division

Research output: Contribution to journal › Review article › peer-review

Abstract

Hospitalization for heart failure (HHF) is commonly associated with symptomatic improvement in response to standard medical therapy, yet there remains a substantial risk of rehospitalization and death. Clinically stable outpatients and decompensated inpatients represent two types of patients with chronic heart failure. In the former, treatment of common heart rhythm disorders with nonpharmacologic electrophysiology-based interventions is of substantial benefit in select patients. The potential benefits of these interventions in the hospitalized setting are not well studied. In this review, current knowledge is discussed and future research directions are suggested with nonpharmacologic electrophysiology-based interventions to reduce the morbidity and mortality associated with patients with HHF.

Original language	English (US)
Pages (from-to)	331-343
Number of pages	13
Journal	Heart Failure Clinics
Volume	9
Issue number	3
DOIs	https://doi.org/10.1016/j.hfc.2013.04.007
State	Published - Jul 2013

Funding

Dr Piccini has received grants for clinical research from Boston Scientific and Johnson & Johnson; is a consultant for Forest Laboratories, Johnson&Johnson, Medtronic, and Sanofi-Aventis. Dr Fonarowis a consultant for Novartis, Medtronic, and Gambro. Dr Knight receives fellowship support from Bard, Biosense Webster, Biotronik, Medtronic, and St Jude Medical; is a speaker for Biosense Webster, Biotronik, Boston Scientific, Medtronic, and St Jude Medical; is a consultant for Biosense Webster, Boston Scientific, and Cameron Health; and is an investigator for Biotronik, Cameron Health, Medtronic, and St Jude Medical. Dr Butler is an investigator for Medtronic, Boston Scientific, and GE Healthcare. Dr Gheorghiade is a consultant for Abbott Laboratories, Astellas, AstraZeneca, Bayer Schering Pharma, CorThera, Cytokinetics Inc, DebioPharm, Errekappa Therapeuitici, GlaxoSmithKline, Johnson & Johnson, Medtronic, Merck, Novartis Pharma, Otsuka Pharmaceuticals, Pericor Therapeutics, Protein Design Laboratories, Sanofi-Aventis, Sigma Tau, and Solvay Pharmaceuticals. All other authors have reported that they have no relationships to disclose relevant to the contents of this article.

Keywords

Electrophysiology
Heart failure
Hospitalization
Outcomes

ASJC Scopus subject areas

Cardiology and Cardiovascular Medicine

Access to Document

10.1016/j.hfc.2013.04.007

Cite this

Wang, N. C., Piccini, J. P., Fonarow, G. C., Knight, B. P., Harinstein, M. E., Butler, J., Lahiri, M. K., Metra, M., Vaduganathan, M., & Gheorghiade, M. (2013). The Potential Role of Nonpharmacologic Electrophysiology-Based Interventions in Improving Outcomes in Patients Hospitalized for Heart Failure. Heart Failure Clinics, 9(3), 331-343. https://doi.org/10.1016/j.hfc.2013.04.007

@article{40bf35544b6d4fbbaaf314dfeb97b837,

title = "The Potential Role of Nonpharmacologic Electrophysiology-Based Interventions in Improving Outcomes in Patients Hospitalized for Heart Failure",

abstract = "Hospitalization for heart failure (HHF) is commonly associated with symptomatic improvement in response to standard medical therapy, yet there remains a substantial risk of rehospitalization and death. Clinically stable outpatients and decompensated inpatients represent two types of patients with chronic heart failure. In the former, treatment of common heart rhythm disorders with nonpharmacologic electrophysiology-based interventions is of substantial benefit in select patients. The potential benefits of these interventions in the hospitalized setting are not well studied. In this review, current knowledge is discussed and future research directions are suggested with nonpharmacologic electrophysiology-based interventions to reduce the morbidity and mortality associated with patients with HHF.",

keywords = "Electrophysiology, Heart failure, Hospitalization, Outcomes",

author = "Wang, \{Norman C.\} and Piccini, \{Jonathan P.\} and Fonarow, \{Gregg C.\} and Knight, \{Bradley Paul\} and Harinstein, \{Matthew E.\} and Javed Butler and Lahiri, \{Marc K.\} and Marco Metra and Muthiah Vaduganathan and Mihai Gheorghiade",

note = "Funding Information: Dr Piccini has received grants for clinical research from Boston Scientific and Johnson \& Johnson; is a consultant for Forest Laboratories, Johnson\&Johnson, Medtronic, and Sanofi-Aventis. Dr Fonarowis a consultant for Novartis, Medtronic, and Gambro. Dr Knight receives fellowship support from Bard, Biosense Webster, Biotronik, Medtronic, and St Jude Medical; is a speaker for Biosense Webster, Biotronik, Boston Scientific, Medtronic, and St Jude Medical; is a consultant for Biosense Webster, Boston Scientific, and Cameron Health; and is an investigator for Biotronik, Cameron Health, Medtronic, and St Jude Medical. Dr Butler is an investigator for Medtronic, Boston Scientific, and GE Healthcare. Dr Gheorghiade is a consultant for Abbott Laboratories, Astellas, AstraZeneca, Bayer Schering Pharma, CorThera, Cytokinetics Inc, DebioPharm, Errekappa Therapeuitici, GlaxoSmithKline, Johnson \& Johnson, Medtronic, Merck, Novartis Pharma, Otsuka Pharmaceuticals, Pericor Therapeutics, Protein Design Laboratories, Sanofi-Aventis, Sigma Tau, and Solvay Pharmaceuticals. All other authors have reported that they have no relationships to disclose relevant to the contents of this article.",

year = "2013",

month = jul,

doi = "10.1016/j.hfc.2013.04.007",

language = "English (US)",

volume = "9",

pages = "331--343",

journal = "Heart Failure Clinics",

issn = "1551-7136",

publisher = "Elsevier Inc.",

number = "3",

}

Wang, NC, Piccini, JP, Fonarow, GC, Knight, BP, Harinstein, ME, Butler, J, Lahiri, MK, Metra, M, Vaduganathan, M & Gheorghiade, M 2013, 'The Potential Role of Nonpharmacologic Electrophysiology-Based Interventions in Improving Outcomes in Patients Hospitalized for Heart Failure', Heart Failure Clinics, vol. 9, no. 3, pp. 331-343. https://doi.org/10.1016/j.hfc.2013.04.007

TY - JOUR

T1 - The Potential Role of Nonpharmacologic Electrophysiology-Based Interventions in Improving Outcomes in Patients Hospitalized for Heart Failure

AU - Wang, Norman C.

AU - Piccini, Jonathan P.

AU - Fonarow, Gregg C.

AU - Knight, Bradley Paul

AU - Harinstein, Matthew E.

AU - Butler, Javed

AU - Lahiri, Marc K.

AU - Metra, Marco

AU - Vaduganathan, Muthiah

AU - Gheorghiade, Mihai

N1 - Funding Information: Dr Piccini has received grants for clinical research from Boston Scientific and Johnson & Johnson; is a consultant for Forest Laboratories, Johnson&Johnson, Medtronic, and Sanofi-Aventis. Dr Fonarowis a consultant for Novartis, Medtronic, and Gambro. Dr Knight receives fellowship support from Bard, Biosense Webster, Biotronik, Medtronic, and St Jude Medical; is a speaker for Biosense Webster, Biotronik, Boston Scientific, Medtronic, and St Jude Medical; is a consultant for Biosense Webster, Boston Scientific, and Cameron Health; and is an investigator for Biotronik, Cameron Health, Medtronic, and St Jude Medical. Dr Butler is an investigator for Medtronic, Boston Scientific, and GE Healthcare. Dr Gheorghiade is a consultant for Abbott Laboratories, Astellas, AstraZeneca, Bayer Schering Pharma, CorThera, Cytokinetics Inc, DebioPharm, Errekappa Therapeuitici, GlaxoSmithKline, Johnson & Johnson, Medtronic, Merck, Novartis Pharma, Otsuka Pharmaceuticals, Pericor Therapeutics, Protein Design Laboratories, Sanofi-Aventis, Sigma Tau, and Solvay Pharmaceuticals. All other authors have reported that they have no relationships to disclose relevant to the contents of this article.

PY - 2013/7

Y1 - 2013/7

N2 - Hospitalization for heart failure (HHF) is commonly associated with symptomatic improvement in response to standard medical therapy, yet there remains a substantial risk of rehospitalization and death. Clinically stable outpatients and decompensated inpatients represent two types of patients with chronic heart failure. In the former, treatment of common heart rhythm disorders with nonpharmacologic electrophysiology-based interventions is of substantial benefit in select patients. The potential benefits of these interventions in the hospitalized setting are not well studied. In this review, current knowledge is discussed and future research directions are suggested with nonpharmacologic electrophysiology-based interventions to reduce the morbidity and mortality associated with patients with HHF.

AB - Hospitalization for heart failure (HHF) is commonly associated with symptomatic improvement in response to standard medical therapy, yet there remains a substantial risk of rehospitalization and death. Clinically stable outpatients and decompensated inpatients represent two types of patients with chronic heart failure. In the former, treatment of common heart rhythm disorders with nonpharmacologic electrophysiology-based interventions is of substantial benefit in select patients. The potential benefits of these interventions in the hospitalized setting are not well studied. In this review, current knowledge is discussed and future research directions are suggested with nonpharmacologic electrophysiology-based interventions to reduce the morbidity and mortality associated with patients with HHF.

KW - Electrophysiology

KW - Heart failure

KW - Hospitalization

KW - Outcomes

UR - http://www.scopus.com/inward/record.url?scp=84879715246&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879715246&partnerID=8YFLogxK

U2 - 10.1016/j.hfc.2013.04.007

DO - 10.1016/j.hfc.2013.04.007

M3 - Review article

C2 - 23809419

AN - SCOPUS:84879715246

SN - 1551-7136

VL - 9

SP - 331

EP - 343

JO - Heart Failure Clinics

JF - Heart Failure Clinics

IS - 3

ER -

The Potential Role of Nonpharmacologic Electrophysiology-Based Interventions in Improving Outcomes in Patients Hospitalized for Heart Failure

Abstract

Funding

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this